Housewife or working mum--each to her own? The relevance of societal factors in the association between social roles and alcohol use among mothers in 16 industrialized countries.

Aims To investigate whether differences in gender-income equity at country level explain national differences in the links between alcohol use, and the combination of motherhood and paid labour. Design Cross-sectional data in 16 established market economies participating in the Gender, Alcohol and Culture: An International Study (GenACIS) study. Setting Population surveys. Participants A total of 12 454 mothers (aged 25-49 years). Measurements Alcohol use was assessed as the quantity per drinking day. Paid labour, having a partner, gender-income ratio at country level and the interaction between individual and country characteristics were regressed on alcohol consumed per drinking day using multi-level modelling. Findings Mothers with a partner who were in paid labour reported consuming more alcohol on drinking days than partnered housewives. In countries with high gender-income equity, mothers with a partner who were in paid labour drank less alcohol per occasion, while alcohol use was higher among working partnered mothers living in countries with lower income equity. Conclusion In countries which facilitate working mothers, daily alcohol use decreases as female social roles increase; in contrast, in countries where there are fewer incentives for mothers to remain in work, the protective effect of being a working mother (with partner) on alcohol use is weaker. These data suggest that a country's investment in measures to improve the compatibility of motherhood and paid labour may reduce women's alcohol use.

Von Wien her, auf Wien hin : Ilse Aichingers "Geographie der eigenen Existenz"

Zusammenfassung In Wien hat Ilse Aichinger (*1921) das Glück der Kindheit erlebt und die Verfolgung durch die Nazis, die ihre jüdischen Verwandten ermordeten. Aichingers Texte zu Wien, die zwischen 1945 und 2005 entstanden sind, suchen in der Topographie der Stadt nach den vergangenen Zeiten und abwesenden Menschen. Sie bilden ein singuläres Erinnerungsprojekt, das einer »Vergangenheitsbewältigung« aus gesicherter Position ein Gedenken entgegengesetzt, das mitsamt seinen Gegenständen im Fluss bliebt. Das Schreiben über Wien bildet einen gewichtigen Strang in einem Werk, das durch Brüche und Lücken gekennzeichnet ist, einen kleinen, immer neu erzählten Stoff und eine immense Spanne an Textformen. In seiner Entwicklung vom Frühwerk, das auf ein emphatisch sich selbst setzendes, existentialistisches Subjekt zentriert ist, zu dem feuilletonistischen Projekt einer »Autobiographie ohne Ich« spiegeln sich 50 Jahre deutscher Literatur- und Kulturgeschichte. Die Einleitung widmet sich der topographischen Poetologie, mit der Ilse Aichinger, Paul Celan, Günter Eich und Ingeborg Bachmann im Diskurs der Standort- und Richtungsbestimmung der Nachkriegsjahre einen eigenen Akzent setzen. Kapitel 1 rekonstruiert am Beispiel der Erzählung Das Plakat (1948) das Raum-, Zeichenund Lektüremodell, das Aichingers hochgradig selbstreferentiellen Texte sowohl abbilden als auch in ihrer Struktur realisieren. Kapitel 2 gewinnt über die Lokalisierung der Schauplätze des Romans Die größere Hoffnung (1948/60) in der Wiener Topographie Aufschluss über die Form des Romans. Der Weg des Romans durch die Stadt integriert die räumlich und zeitlich diskontinuierlichen Kapitel zu einem übergreifenden Ganzen. Kapitel 3 widmet sich den szenischen Dialogen Zu keiner Stunde (1957), die durch ihre Titel in Wien lokalisiert sind. Zeichnet Die größere Hoffnung eine Topographie des Terrors, gehen die Dialoge von Orten der Kunst und des Gedenkens aus und thematisieren die Bedingungen eines Erinnerns, das lebendig bleibt. Kapitel 4 zeichnet nach, wie in den Prosagedichten im Band Kurzschlüsse (1954/2001) und in der autobiographischen Prosa in Kleist, Moos, Fasane (1987) die Gegenwartsebene eines erinnernden Ichs entsteht, die sich zunehmend dynamisiert und mit dem Schreibvorgang verbindet. Kapitel 5 beschäftigt sich mit dem feuilletonistischen Spätwerk, in dem mit dem Kino und dem Café auch die Orte des Erinnerns und Schreibens Teil der Wiener Topographie werden. Film und Verhängnis. Blitzlichter auf ein Leben (2001) ist eine Autobiographie, die auf das Verschwinden der eigenen Person zielt.

Dedication of monuments erected by the state of Iowa,commemorating the death, suffering and valor of her soldiers on the battlefields of Vickburg, Lookout Mountain, Missionary Ridge, Shiloh, and in the Confederate prison at Andersonville,November twelfth to twenty-sixth, nineteen hundred and six,1908.

This book contains information on the dedication ceremony of Iowa monuments on the southern battlefields from the civil war and their final transfer made to the care of the general government. It includes history of the battles, photos and maps.

Kurdi Hedjaz : eupsem ; Hedjazkiar Gazel : her sinédé / Hafiz Riza Bey, chant [acc. instr.]

[Traditions. Asie. Turquie]

Kurdili Hédjaz : eu mur azdir ; Kurdi Hedjaskar : her quimdé / Deniz Kizi Eftalia Hanoum, chant [acc. instr.]

[Traditions. Asie. Turquie]

Iowa, the anniversary of her statehood, December 28 : a few books about Iowa, 1902

This leaflet includes information on books and reference materials that can found in libraries on the Statehood of Iowa.

Lapatax: Safety profile of neoadjuvant lapatinib combined with docetaxel in Her 2/neu overexpressing breast cancer - EORTC protocol 10054

Objective: To assess the safety/tolerability of the combination lapatinib (L) and docetaxel (D) in patients with Her 2/neu overexpressing breast cancer (BC). This study is important as it will define how to deliver lapatinib with taxotere, a highly active drug in breast cancer. Patients and Methods: Female patients (pts) with locally advanced, inflammatory or large operable BC were treated with escalating doses of L from 1000 to 1250 mg/day, in combination with D given IV every 21 days at doses ranging from 75 to 100 mg/m2 for 4 cycles. At least 3 pts were treated at each dose level. The definition of dose limiting toxicity (DLT) is based on the toxicity assessed at cycle 1 as follows: any grade 3−4 non hematological toxicity, ANC < 0.5 G/L lasting for 7 days or more, febrile neutropenia or thrombocytopenia <25 G/L. GCSF was not permitted as primary prophylaxis. Core biopsies were mandatory at baseline and after cycle 4. Pharmcokinetic (PK) samples were collected on day 1 of cycles 1 and 2. Results: To date, 18 pts with a median age of 53 years (range 36−65) have been enrolled at 5 Dose Levels (DLs). The toxicity profile for 18 patients (68 documented cycles) is summarized below. At DL5 (1000/100), 2 pts had DLTs (neutropenia grade 4 _7 days and febrile neutropenia), and 3 additional pts were enrolled with primary prophylactic G-CSF. As expected, the safety profile improved and the dose escalation will continue with prophylactic G-CSF to investigate DL6 (1250/100). These findings are consistent with published Phase I data for this combination [1]. N= 18 patients n (%) Grade 1 Grade 2 Grade 3 Grade 4 neutropenia 1 (6) 3 (17) 13 (72) febrile neutropenia 2 (11) fatigue 8 (44) 7 (39) diarrhoea 9 (50) 3 (17) pain: joint/muscle/other 5 (28)/4 (22)/3 (17) 4 (22)/4 (22)/3 (17) 0/0/1 (6) constipation 2 (11) 3 (17) 1 (6) elevated transaminases SGPT/SGOT 7 (39)/5 (28) Conclusions: The main toxicity of the L + D combination is haematological and was reached at DL5 (1000/100), without primary GCSF. An additional DL6 with primary prophylactic GCSF is being investigated (1250/100). PK data will be presented at the meeting plus the recommended dose for phase II studies.

Can resistance to trastuzumab be reversed by endocrine therapy? Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive, advanced breast cancer: a proof-of-concept trial (SAKK 23/03)

Introduction: Trastuzumab (T) is a cornerstone in the treatment of patients with HER2-overexpressing advanced breast cancer and development of resistance to T is a major therapeutic problem. HER-2 is part of a highly interactive signaling network that may impair efficacy of endocrine therapy. A sequential treatment design was chosen in this trial to ensure complete resistance to single agent therapy before receiving both a non-steroidal aromatase inhibitor (AI) and T. Any kind of clinical activity with combined treatment of AI and T after progression of single agent treatments could indicate restoration of sensitivity as a consequence of cross-talking and networking between both pathways. Methods: Key eligibility criteria included postmenopausal patients (pts.) with advanced, measurable, HER-2 positive (assessed by FISH, ratio (≥2)), HR positive disease and progression on prior treatment with a non-steroidal AI, e.g. letrozole or anastrozole, either in an adjuvant or advanced setting. Pts. received standard dose T monotherapy either weekly or three-weekly in step 1 and upon disease progression, continued T in combination with letrozole in step 2. The primary endpoint was clinical benefit response (CBR: CR, PR or SD for at least 24 weeks (+/- 1 week) according to RECIST) in step 2. Results: Thirteen pts. were enrolled in five centers in Switzerland. In step 1, six pts. (46%) achieved CBR. Median time to progression (TTP) was 161 days (Range: 50 - 627). Based on data collected until the end of May 2010, CBR was observed in seven out of the eleven evaluable pts. (64%) in step 2, including one pt. with partial response. Four of the seven pts. within step 2 that achieved CBR also had CBR in step 1. Seven out of eleven pts. have documented tumor progression during step 2 treatment. Median TTP for all eleven pts. was 184 days (range 61 - 471). Mean time on study treatment (TTP in step 1 plus TTP in step 2) for pts. reaching step 2 was 380 days (range 174 - 864). Adverse events were generally mild. Conclusion: Results of this proof-of-principle trial suggest that complete resistance to both AI and T can be overcome in a proportion of pts. by combined treatment of AI and T, as all pts. served as their own control. Our results appear promising for a new treatment strategy which offers a chemotherapy-free and well-tolerated option for at least a subset of the pts. with HR positive, HER-2 positive breast cancer. Further trials will need to corroborate this finding.

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressatrade mark)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)

Intrinsic resistance to the epidermal growth factor receptor (EGFR; HER1) tyrosine kinase inhibitor (TKI) gefitinib, and more generally to EGFR TKIs, is a common phenomenon in breast cancer. The availability of molecular criteria for predicting sensitivity to EGFR-TKIs is, therefore, the most relevant issue for their correct use and for planning future research. Though it appears that in non-small-cell lung cancer (NSCLC) response to gefitinib is directly related to the occurrence of specific mutations in the EGFR TK domain, breast cancer patients cannot be selected for treatment with gefitinib on the same basis as such EGFR mutations have beenreported neither in primary breast carcinomas nor in several breast cancer cell lines. Alternatively, there is a generalagreement on the hypothesis that the occurrence of molecular alterations that activate transduction pathways downstreamof EGFR (i.e., MEK1/MEK2 - ERK1/2 MAPK and PI-3'K - AKT growth/survival signaling cascades) significantly affect the response to EGFR TKIs in breast carcinomas. However,there are no studies so far addressing a role of EGF-related ligands as intrinsic breast cancer cell modulators of EGFR TKIefficacy. We recently monitored gene expression profiles andsub-cellular localization of HER-1/-2/-3/-4 related ligands (i.e., EGF, amphiregulin, transforming growth factor-α, ß-cellulin,epiregulin and neuregulins) prior to and after gefitinib treatment in a panel of human breast cancer cell lines. First, gefitinibinduced changes in the endogenous levels of EGF-related ligands correlated with the natural degree of breast cancer cellsensitivity to gefitinib. While breast cancer cells intrinsically resistant to gefitinib (IC50 ≥15 μM) markedly up-regulated(up to 600 times) the expression of genes codifying for HERspecific ligands, a significant down-regulation (up to 106 times)of HER ligand gene transcription was found in breast cancer cells intrinsically sensitive to gefitinib (IC50 ≤1 μM). Second,loss of HER1 function differentially regulated the nuclear trafficking of HER-related ligands. While gefitinib treatment induced an active import and nuclear accumulation of the HER ligand NRG in intrinsically gefitinib-resistant breastcancer cells, an active export and nuclear loss of NRG was observed in intrinsically gefitinib-sensitive breast cancer cells.In summary, through in vitro and pharmacodynamic studies we have learned that, besides mutations in the HER1 gene,oncogenic changes downstream of HER1 are the key players regulating gefitinib efficacy in breast cancer cells. It now appears that pharmacological inhibition of HER1 functionalso leads to striking changes in both the gene expression and the nucleo-cytoplasmic trafficking of HER-specific ligands,and that this response correlates with the intrinsic degree of breast cancer sensitivity to the EGFR TKI gefitinib. Therelevance of this previously unrecognized intracrine feedback to gefitinib warrants further studies as cancer cells could bypassthe antiproliferative effects of HER1-targeted therapeutics without a need for the overexpression and/or activation of other HER family members and/or the activation of HER-driven downstream signaling cascades

Emmy Noether: her heritage

Emmy Noether is my role model for the following reasons. She is one of the most important mathematician and physicists of the 20 century; She fought to be a scientist in times where women were not allowed to be one; She was a leader that gathered around her a large school of students and collaborators. In the lecture these reasons will be substantiated with historical facts. In addition, a general assessment of the significance of her ideas and works, from her times until today, will be advanced.

Her onginþ seo boc: On the loss and retention of grammatical gender in Early Middle English

Tutkielma käsittelee kieliopillisen suvun säilymistä myöhäisessä muinaisenglannissa (Late Old English) ja varhaiskeskienglannissa (Early Middle English). Tutkielman tavoitteena on päätellä, kuinka kieliopillinen suku säilyy kolmessa muinaisenglannin/varhaiskeskienglannin aikakautta edustavassa tekstissä. Lähdeaineisto on valittu edustamaan aikaa (1150-1225), jolloin kieliopillisen suvun on sanottu kadonneen englannin kielestä. Lähdeaineisto myös edustaa kahta eri tekstilajia, ja tarjoaa siten aineistoa niiden väliseen vertailuun. Aineistosta on analysoitu nominien päätteitä, demonstratiivipronomineja sekä anaforisia persoonapronomineja, joissa substantiivien kieliopillinen suku näkyy. Osa anaforisista viittauksista on selitettävissä personifikaatiolla, jolloin elottomiin objekteihin tai käsitteisiin on liitetty inhimillistäviä piirteitä. Tutkimuksen perusteella kieliopillinen suku säilyy vielä joissakin muodoissa 1200- luvulle saakka. Merkittävää on aineistossa esiintyvä runsas vaihtelu ja pyhimyselämänkertojen ja lääketieteellisen tekstin väliset erot.

Chorale Prelude "Vom Himmel hoch, da komm' ich her"

Soitinnus: Urut.